John Desjarlais

John Desjarlais

Company: Xencor

Job title: CSO


Dr. Desjarlais is the Senior Vice President, Research and Chief Scientific Officer at Xencor, Inc.  Since joining Xencor in 2001, Dr. Desjarlais has overseen the company’s engineering, discovery, and preclinical work on antibodies and other proteins.  With his coworkers, Dr. Desjarlais has developed several novel technologies for the optimization of antibodies and other proteins, including a platform for generation of bispecific antibodies, and has led the discovery of multiple therapeutic antibody candidates, including CD3 bispecific antibodies, checkpoint bispecific antibodies, and cytokine-Fc fusions for treatment of a variety of diseases. Dr. Desjarlais oversees all of Xencor’s discovery research and preclinical activities, from project conception and candidate generation through preclinical proof-of-concept and early development.  Prior to Xencor, Dr. Desjarlais was an Assistant Professor of Chemistry at Penn State University (1997-2001), where he developed and tested methods for the de novo design of protein sequences.  He began his work in the field of protein design as a Jane Coffin Childs Fellow at U.C. Berkeley.  Dr. Desjarlais holds a Ph.D. in Biophysics from the Johns Hopkins University and a B.S. degree in Physics from the University of Massachusetts, Amherst.


Optimizing Therapeutic Index and Other Properties with Potency Reduction and Bivalent Target Engagement 1:45 pm

Lessons from clinical data on CD123 x CD3 and CD20 x CD3 Reducing CD3 affinity to reduce CRS and improve exposure Bivalent engagement and affinity tuning to increase tumor vs normal reactivityRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.